Abstract
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effectiveness and safety of CBD in the treatment of people with schizophrenia.
| Originalsprog | Engelsk |
|---|---|
| Artikelnummer | CD014602 |
| Tidsskrift | Cochrane Database of Systematic Reviews |
| Vol/bind | 2022 |
| Udgave nummer | 11 |
| ISSN | 1465-1858 |
| DOI | |
| Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:• Diana Buitrago-Garcia receives grants from the Swiss Government Excellence Scholarship and The Swiss School of Public Health Global P3HS, Switzerland
Funding Information:
Cochrane Schizophrenia's Editorial Base at the University Of Nottingham, Nottingham (UK) produces and maintains standard text for use in the Methods section of their reviews. We have used this text as the basis of what appears here and adapted it as required. Cochrane Schizophrenia supported the authors in the development of this Protocol. The following people conducted the editorial process for this article: Sign-off Editor (final editorial decision): Mahesh Jayaram, University of Melbourne (Australia) Managing Editor (selected peer reviewers, collated peer-reviewer comments, provided editorial guidance to authors, edited the article): Hui Wu, Technical University of Munich (Germany) Contact Editor (provided comments and guidance to authors): Ajit Kumar, Monash University, Monash Children's Hospital (Australia) Copy Editor (copy-editing and production): Julia Turner Information Specialist (search strategy): Anne Parkhill, University of Melbourne (Australia) Peer-reviewers* (provided comments and recommended an editorial decision): Wojciech Mędrala, Medical University of Silesia, Department of Psychiatry and Psychotherapy in Katowice (Poland); Michel Sabe, Geneva University Hospitals (Switzerland) (clinical/content review) Sign-off Editor (final editorial decision): Mahesh Jayaram, University of Melbourne (Australia) Managing Editor (selected peer reviewers, collated peer-reviewer comments, provided editorial guidance to authors, edited the article): Hui Wu, Technical University of Munich (Germany) Contact Editor (provided comments and guidance to authors): Ajit Kumar, Monash University, Monash Children's Hospital (Australia) Copy Editor (copy-editing and production): Julia Turner Information Specialist (search strategy): Anne Parkhill, University of Melbourne (Australia) Peer-reviewers* (provided comments and recommended an editorial decision): Wojciech Mędrala, Medical University of Silesia, Department of Psychiatry and Psychotherapy in Katowice (Poland); Michel Sabe, Geneva University Hospitals (Switzerland) (clinical/content review) The previous Editorial Base of Cochrane Schizophrenia also supported this work: Co-ordinating Editor: Clive Adams (before 2020) Managing Editor: Claire Irving (before 2020) Assistant Managing Editor: Ghazaleh Aali, University College London (UK) (before April 2021) Co-ordinating Editor: Clive Adams (before 2020) Managing Editor: Claire Irving (before 2020) Assistant Managing Editor: Ghazaleh Aali, University College London (UK) (before April 2021) *Peer-reviewers are members of Cochrane Schizophrenia, and provided peer-review comments on this article, but they were not otherwise involved in the editorial process or decision-making for this article.
Publisher Copyright:
Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.